Product Information

CAS No.	163451-80-7
Product Name	Talviraline

Heavy Atom Count	22	Rotatable Bond Count	4
Atom Stereo Count	1	Bond Stereo Count	0
HBA	5	HBD	1
TPSA	50.800 Å²	Charge	0
Exact Mass	340.09153	Complexity	577.91
pKa	5.875	XLogP	3.531

Studies related to this compound and its mechanism of action

Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.

Molecular pharmacology • Vol. 57, Issue 5 • 2000

PMID: 10779379

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.

Journal of medicinal chemistry • Vol. 42, Issue 20 • 1999

PMID: 10514285 DOI: 10.1021/jm990095j

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

AIDS research and human retroviruses • Vol. 14, Issue 3 • 1998

PMID: 9491916 DOI: 10.1089/aid.1998.14.255

Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).

Biochemical pharmacology • Vol. 55, Issue 5 • 1998

PMID: 9515572 DOI: 10.1016/s0006-2952(97)00506-6

Talviraline

In Stock•Starting at $166 for 1 mg

CAS No.	163451-80-7
MDL No.	N/A
MF	C₁₅H₂₀N₂O₃S₂
MW	340.50
InChI Key	GWKIPRVERALPRD-ZDUSSCGKSA-N

CUSTOM SYNTHESIS

Pricing & Availability

Pack Size	Purity	Price	Availability
1 mg	To Be Confirmed	$166	In Stock
5 mg	To Be Confirmed	$408	In Stock
10 mg	To Be Confirmed	$612	In Stock
25 mg	To Be Confirmed	$996	In Stock
50 mg	To Be Confirmed	$1400	In Stock

Product Information

CAS No.	163451-80-7
Product Name	Talviraline

Heavy Atom Count	22	Rotatable Bond Count	4
Atom Stereo Count	1	Bond Stereo Count	0
HBA	5	HBD	1
TPSA	50.800 Å²	Charge	0
Exact Mass	340.09153	Complexity	577.91
pKa	5.875	XLogP	3.531

Talviraline

Pricing & Availability

Product Information

Properties

Talviraline

Pricing & Availability

Product Information

Properties

Documentation

Talviraline

Pricing & Availability

Product Information

Properties

Related Articles

Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

Talviraline

Pricing & Availability

Product Information

Properties

Related Articles

Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

Documentation